PROMOTION OF SCIENTIFIC RESEARCH IN AYUSH SYSTEMS

The Ministry of Ayush's comprehensive push for scientific validation of traditional medicine systems represents a transformative shift in India's healthcare governance, rooted in constitutional mandates and global health diplomacy. Article 47 of the Directive Principles of State Policy explicitly directs the State to raise nutrition levels and improve public health, while Article 21's expansive interpretation by the Supreme Court includes the right to health — making evidence-based integration of Ayush systems a constitutional imperative. The Ayurgyan Scheme (launched FY 2021-22) and its ABIHR component (added FY 2023-24) operationalize this by bridging ancient wisdom with modern scientific rigor, allocating ₹58.28 crore for 11 high-end Ayurveda biology projects and ₹11.82 crore for 73 innovation projects — a clear signal of fiscal prioritization. The five research councils (CCRAS, CCRH, CCRUM, CCRS, CCRYN) form the backbone of this ecosystem, with fund utilization rates exceeding 95% for most councils in FY 2024-25 — CCRAS utilized 100% of its ₹469.72 crore allocation, CCRUM 100% of ₹190.05 crore — reflecting institutional maturity. Their work spans clinical trials, drug standardization, and epidemic research, directly supporting the National Health Policy 2017's vision of 'mainstreaming Ayush'. Internationally, India's leadership is crystallized through WHO collaboration: the ICD-11 Traditional Medicine Module-2 launch in New Delhi (Jan 10, 2024) standardized morbidity codes for Ayurveda, Siddha, Unani — a historic step for global health data interoperability. The WHO Global Traditional Medicine Centre (GTMC) in Jamnagar, Gujarat, positions India as the global knowledge hub for traditional medicine, aligning with SDG 3 (Universal Health Coverage). Bilateral MoUs with Germany, South Africa, Iran, UAE, and others — including CCRH's 12 MoUs for homeopathy and CCRUM's Unani chairs — demonstrate soft power projection through medical diplomacy. Domestically, PCIM&H's 'One Herb, One Standard' initiative via MoU with Indian Pharmacopoeia Commission (Ministry of Health & Family Welfare) addresses a critical regulatory gap: harmonizing Ayush and modern pharmacopoeial standards. Partnerships with CSIR institutes (CIMAP, IHBT, NBRI) and Ayush councils create a robust quality assurance framework, essential for export competitiveness — India's Ayush exports crossed $1.5 billion in 2023. Future implications are profound: evidence generation through centers like GTMC and ABIHR projects could enable Ayush integration into Ayushman Bharat's Health and Wellness Centres, reducing out-of-pocket expenditure. The two WHO Global Summits on Traditional Medicine (2023, 2025) in India signal sustained global momentum. However, challenges remain — ensuring rigorous clinical trial standards, addressing intellectual property concerns under the Biological Diversity Act 2002, and scaling quality manufacturing under the Drugs and Cosmetics Act 1940 amendments. This multi-pronged strategy — domestic research funding, international standardization, regulatory harmonization — positions India to lead the global integrative healthcare revolution, turning traditional knowledge into a 21st-century public health asset.